GI-129471 | 130370-59-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: GI-129471
• 英文别名: (2S,3R)-N-hydroxy-N'-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)-2-(phenylsulfanylmethyl)butanediamide
• CAS: 130370-59-1
• 化学式: C₂₅H₃₃N₃O₄S
• 分子量: 471.621
• InChiKey: UBFGIEDUTRCMEQ-FSSWDIPSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  33
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  133
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  (2R)-2-[1-(tert-butoxycarbonyl)vinyl]-4-methylpentanoic acid 在 N-甲基吗啉 、 N-羟基-7-氮杂苯并三氮唑 、 乙胺嗪 、 丹酰尸胺 、 盐酸羟胺 、 1-羟基苯并三唑 、 三乙胺 、 三氟乙酸 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 GI-129471
  参考文献：
  名称：

  Selective inhibition of low affinity IgE receptor (CD23) processing

  摘要：

  A series of hydroxamic acids related to the non-selective matrix metalloproteinase inhibitor Batimastat has been prepared, some members of which are potent inhibitors of the processing of the low affinity IgE receptor (CD 23). Increased activity is obtained by appropriate substitution at the a-position, whilst selectivity is gained by use of a P1' benzyl group in conjunction with a C-terminal primary amide. (C) 1997 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(97)10149-4

文献信息

• UTILIZATION OF TACE INHIBITORS FOR THE TREATMENT OF ACNE
  申请人：AUBERT JÉRÔME

  公开号：US20100168089A1

  公开（公告）日：2010-07-01

  An in vitro method of screening for candidate compounds for the preventive or curative treatment of acne entails determination of the ability of a compound to inhibit the expression or the activity of TACE, and also to the administration of inhibitors of the expression or of the activity of this enzyme, in the treatment of acne.

  一种体外筛选预防或治疗痤疮候选化合物的方法，需要确定化合物抑制TACE（酶）表达或活性的能力，并且使用这种酶表达或活性的抑制剂进行痤疮治疗。
• Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
  申请人：Pharmacia Corporation

  公开号：US20040122011A1

  公开（公告）日：2004-06-24

  The present invention provides compositions and methods to treat, prevent or inhibit a neoplasia, a neoplasia-related disorder, pain, inflammation, an inflammatory-related disorder, a vaso-occlusive event or a vaso-occlusive-related disorder in a mammal using a combination of a COX-2 inhibitor and a TACE inhibitor.

  本发明提供了一种使用COX-2抑制剂和TACE抑制剂的组合物和方法，以治疗、预防或抑制哺乳动物中的肿瘤、肿瘤相关疾病、疼痛、炎症、炎症相关疾病、血管闭塞性事件或血管闭塞性相关疾病。
• METHODS FOR DRUG SCREEN USING ZEBRAFISH MODEL AND THE COMPOUNDS SCREENED THEREFROM
  申请人：National Taiwan University

  公开号：US20140073611A1

  公开（公告）日：2014-03-13

  The disclosure relates to a platform of using zebrafish in screening candidates for treating and/or preventing myopia and keratoconus disease. The disclosure is mainly based on that Lumican, one of several SLRPs, plays an important role in the regulation of fibrillogenesis or the genes affecting the size of eyeballs in zebrafish, in addition to playing an important role in clinical myopia. Therefore, the disclosure uses the established zebrafish model to further identify the drugs affecting the expression of lumican and collagen fibrillogenesis, and/or the regulation of eyeball size. These drugs are potential candidates for treating myopia and/or keratoconus disease.
• [EN] PHARMACOLOGICAL CHAPERONES FOR THE TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] CHAPERONS PHARMACOLOGIQUES POUR LE TRAITEMENT DE LA MALADIE D’ALZHEIMER
  申请人：AMICUS THERAPEUTICS INC

  公开号：WO2011011181A1

  公开（公告）日：2011-01-27

  The invention relates to methods of enhancing normal α-secretase expression, and to enhancing expression of an α-secretase having a mutation which affects protein folding and/or processing of the α-secretase. The invention provides a method of treating an individual having a condition in which increased expression or activity of an α-secretase in the central nervous system would be beneficial, by administering an effective amount of a pharmacologic chaperone for the α-secretase. The invention provides α-secretase inhibitors which have been identified as specific pharmacologic chaperones which enhance expression or enzymatic activity of α-secretase in the central nervous system.
• Selective inhibition of low affinity IgE receptor (CD23) processing
  作者：Stuart Bailey、Brian Bolognese、Derek R Buckle、Andrew Faller、Sally Jackson、Pearl Louis-Flamberg、Mark McCord、Ruth J Mayer、Lisa A Marshall、David G Smith

  DOI：10.1016/s0960-894x(97)10149-4

  日期：1998.1

  A series of hydroxamic acids related to the non-selective matrix metalloproteinase inhibitor Batimastat has been prepared, some members of which are potent inhibitors of the processing of the low affinity IgE receptor (CD 23). Increased activity is obtained by appropriate substitution at the a-position, whilst selectivity is gained by use of a P1' benzyl group in conjunction with a C-terminal primary amide. (C) 1997 Elsevier Science Ltd. All rights reserved.